Numinus Wellness Inc.
Numinus Wellness Inc. (NUMIF) Stock Competitors & Peer Comparison
See (NUMIF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUMIF | $0.04 | +26.61% | 12.6M | -1.31 | -$0.03 | N/A |
| FSNUY | $13.82 | -1.99% | 124.4B | 23.41 | $0.59 | +1.99% |
| FSNUF | $56.35 | +0.00% | 31.7B | 23.98 | $2.35 | +2.01% |
| JDHIF | $8.30 | +0.00% | 26.5B | 39.50 | $0.21 | N/A |
| JDHIY | $6.82 | +0.00% | 21.8B | 32.48 | $0.21 | N/A |
| FMCQF | $51.00 | +0.00% | 15B | 19.62 | $2.60 | +3.19% |
| BDUUY | $32.33 | +0.00% | 12.8B | 28.36 | $1.14 | +2.79% |
| IHHHF | $1.19 | +0.00% | 10.5B | 17.00 | $0.07 | +2.00% |
| BDULF | $0.62 | +1.64% | 9.9B | 20.67 | $0.03 | +3.59% |
| BDUUF | $0.59 | +0.00% | 9.4B | 19.67 | $0.03 | +3.78% |
Stock Comparison
NUMIF vs FSNUY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, FSNUY has a market cap of 124.4B. Regarding current trading prices, NUMIF is priced at $0.04, while FSNUY trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas FSNUY's P/E ratio is 23.41. In terms of profitability, NUMIF's ROE is -4.41%, compared to FSNUY's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to FSNUY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FSNUY's competition here
NUMIF vs FSNUF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, FSNUF has a market cap of 31.7B. Regarding current trading prices, NUMIF is priced at $0.04, while FSNUF trades at $56.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas FSNUF's P/E ratio is 23.98. In terms of profitability, NUMIF's ROE is -4.41%, compared to FSNUF's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to FSNUF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FSNUF's competition here
NUMIF vs JDHIF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, JDHIF has a market cap of 26.5B. Regarding current trading prices, NUMIF is priced at $0.04, while JDHIF trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas JDHIF's P/E ratio is 39.50. In terms of profitability, NUMIF's ROE is -4.41%, compared to JDHIF's ROE of +0.08%. Regarding short-term risk, NUMIF is more volatile compared to JDHIF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JDHIF's competition here
NUMIF vs JDHIY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, JDHIY has a market cap of 21.8B. Regarding current trading prices, NUMIF is priced at $0.04, while JDHIY trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas JDHIY's P/E ratio is 32.48. In terms of profitability, NUMIF's ROE is -4.41%, compared to JDHIY's ROE of +0.08%. Regarding short-term risk, NUMIF is more volatile compared to JDHIY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JDHIY's competition here
NUMIF vs FMCQF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, FMCQF has a market cap of 15B. Regarding current trading prices, NUMIF is priced at $0.04, while FMCQF trades at $51.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas FMCQF's P/E ratio is 19.62. In terms of profitability, NUMIF's ROE is -4.41%, compared to FMCQF's ROE of +0.05%. Regarding short-term risk, NUMIF is more volatile compared to FMCQF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FMCQF's competition here
NUMIF vs BDUUY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BDUUY has a market cap of 12.8B. Regarding current trading prices, NUMIF is priced at $0.04, while BDUUY trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, NUMIF's ROE is -4.41%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to BDUUY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDUUY's competition here
NUMIF vs IHHHF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, IHHHF has a market cap of 10.5B. Regarding current trading prices, NUMIF is priced at $0.04, while IHHHF trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas IHHHF's P/E ratio is 17.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to IHHHF's ROE of +0.08%. Regarding short-term risk, NUMIF is more volatile compared to IHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check IHHHF's competition here
NUMIF vs BDULF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BDULF has a market cap of 9.9B. Regarding current trading prices, NUMIF is priced at $0.04, while BDULF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BDULF's P/E ratio is 20.67. In terms of profitability, NUMIF's ROE is -4.41%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to BDULF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDULF's competition here
NUMIF vs BDUUF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BDUUF has a market cap of 9.4B. Regarding current trading prices, NUMIF is priced at $0.04, while BDUUF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BDUUF's P/E ratio is 19.67. In terms of profitability, NUMIF's ROE is -4.41%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to BDUUF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDUUF's competition here
NUMIF vs WFHG Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, WFHG has a market cap of 6.7B. Regarding current trading prices, NUMIF is priced at $0.04, while WFHG trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas WFHG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to WFHG's ROE of +0.28%. Regarding short-term risk, NUMIF is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check WFHG's competition here
NUMIF vs RMYHY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RMYHY has a market cap of 5.7B. Regarding current trading prices, NUMIF is priced at $0.04, while RMYHY trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RMYHY's P/E ratio is 571.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to RMYHY's ROE of +0.01%. Regarding short-term risk, NUMIF is more volatile compared to RMYHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RMYHY's competition here
NUMIF vs RMSYF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RMSYF has a market cap of 5.5B. Regarding current trading prices, NUMIF is priced at $0.04, while RMSYF trades at $23.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RMSYF's P/E ratio is 474.30. In terms of profitability, NUMIF's ROE is -4.41%, compared to RMSYF's ROE of +0.01%. Regarding short-term risk, NUMIF is more volatile compared to RMSYF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RMSYF's competition here
NUMIF vs ANHGY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, NUMIF is priced at $0.04, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, NUMIF's ROE is -4.41%, compared to ANHGY's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ANHGY's competition here
NUMIF vs BUHPF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BUHPF has a market cap of 3.9B. Regarding current trading prices, NUMIF is priced at $0.04, while BUHPF trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BUHPF's P/E ratio is 17.96. In terms of profitability, NUMIF's ROE is -4.41%, compared to BUHPF's ROE of +0.27%. Regarding short-term risk, NUMIF is more volatile compared to BUHPF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BUHPF's competition here
NUMIF vs BUGDF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BUGDF has a market cap of 3.4B. Regarding current trading prices, NUMIF is priced at $0.04, while BUGDF trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BUGDF's P/E ratio is 16.27. In terms of profitability, NUMIF's ROE is -4.41%, compared to BUGDF's ROE of +0.27%. Regarding short-term risk, NUMIF is more volatile compared to BUGDF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BUGDF's competition here
NUMIF vs MCVEF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MCVEF has a market cap of 3B. Regarding current trading prices, NUMIF is priced at $0.04, while MCVEF trades at $19.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MCVEF's P/E ratio is 82.63. In terms of profitability, NUMIF's ROE is -4.41%, compared to MCVEF's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to MCVEF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCVEF's competition here
NUMIF vs ORPEF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, NUMIF is priced at $0.04, while ORPEF trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, NUMIF's ROE is -4.41%, compared to ORPEF's ROE of -0.23%. Regarding short-term risk, NUMIF is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ORPEF's competition here
NUMIF vs MCVEY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MCVEY has a market cap of 2.2B. Regarding current trading prices, NUMIF is priced at $0.04, while MCVEY trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, NUMIF's ROE is -4.41%, compared to MCVEY's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to MCVEY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCVEY's competition here
NUMIF vs TTALF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, TTALF has a market cap of 1.6B. Regarding current trading prices, NUMIF is priced at $0.04, while TTALF trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas TTALF's P/E ratio is 19.33. In terms of profitability, NUMIF's ROE is -4.41%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to TTALF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check TTALF's competition here
NUMIF vs RAFLF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, NUMIF is priced at $0.04, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, NUMIF's ROE is -4.41%, compared to RAFLF's ROE of +0.03%. Regarding short-term risk, NUMIF is more volatile compared to RAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RAFLF's competition here
NUMIF vs RHCGF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RHCGF has a market cap of 1.5B. Regarding current trading prices, NUMIF is priced at $0.04, while RHCGF trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RHCGF's P/E ratio is -3.99. In terms of profitability, NUMIF's ROE is -4.41%, compared to RHCGF's ROE of -0.07%. Regarding short-term risk, NUMIF is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check RHCGF's competition here
NUMIF vs RYHTY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RYHTY has a market cap of 1.4B. Regarding current trading prices, NUMIF is priced at $0.04, while RYHTY trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RYHTY's P/E ratio is -3.91. In terms of profitability, NUMIF's ROE is -4.41%, compared to RYHTY's ROE of -0.02%. Regarding short-term risk, NUMIF is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RYHTY's competition here
NUMIF vs LWSCF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, LWSCF has a market cap of 1.2B. Regarding current trading prices, NUMIF is priced at $0.04, while LWSCF trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas LWSCF's P/E ratio is 46.08. In terms of profitability, NUMIF's ROE is -4.41%, compared to LWSCF's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to LWSCF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check LWSCF's competition here
NUMIF vs LTGHY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, LTGHY has a market cap of 1.1B. Regarding current trading prices, NUMIF is priced at $0.04, while LTGHY trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas LTGHY's P/E ratio is -21.20. In terms of profitability, NUMIF's ROE is -4.41%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, NUMIF is more volatile compared to LTGHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check LTGHY's competition here
NUMIF vs LTGHF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, LTGHF has a market cap of 1.1B. Regarding current trading prices, NUMIF is priced at $0.04, while LTGHF trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas LTGHF's P/E ratio is -19.69. In terms of profitability, NUMIF's ROE is -4.41%, compared to LTGHF's ROE of +0.40%. Regarding short-term risk, NUMIF is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check LTGHF's competition here
NUMIF vs RHKJF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, NUMIF is priced at $0.04, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, NUMIF's ROE is -4.41%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, NUMIF is more volatile compared to RHKJF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RHKJF's competition here
NUMIF vs RKAGY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RKAGY has a market cap of 986.6M. Regarding current trading prices, NUMIF is priced at $0.04, while RKAGY trades at $7.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RKAGY's P/E ratio is 22.33. In terms of profitability, NUMIF's ROE is -4.41%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, NUMIF is more volatile compared to RKAGY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RKAGY's competition here
NUMIF vs NWKHY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NWKHY has a market cap of 953.1M. Regarding current trading prices, NUMIF is priced at $0.04, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NWKHY's P/E ratio is 10.70. In terms of profitability, NUMIF's ROE is -4.41%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, NUMIF is more volatile compared to NWKHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NWKHY's competition here
NUMIF vs WHTCF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, WHTCF has a market cap of 892.8M. Regarding current trading prices, NUMIF is priced at $0.04, while WHTCF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas WHTCF's P/E ratio is -10.07. In terms of profitability, NUMIF's ROE is -4.41%, compared to WHTCF's ROE of -0.15%. Regarding short-term risk, NUMIF is more volatile compared to WHTCF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check WHTCF's competition here
NUMIF vs EXETF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, EXETF has a market cap of 792.4M. Regarding current trading prices, NUMIF is priced at $0.04, while EXETF trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas EXETF's P/E ratio is 13.51. In terms of profitability, NUMIF's ROE is -4.41%, compared to EXETF's ROE of +0.65%. Regarding short-term risk, NUMIF is more volatile compared to EXETF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check EXETF's competition here
NUMIF vs JXFGF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, JXFGF has a market cap of 750.5M. Regarding current trading prices, NUMIF is priced at $0.04, while JXFGF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, NUMIF is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check JXFGF's competition here
NUMIF vs KDGTF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, NUMIF is priced at $0.04, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, NUMIF's ROE is -4.41%, compared to KDGTF's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check KDGTF's competition here
NUMIF vs ORRRY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, NUMIF is priced at $0.04, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, NUMIF's ROE is -4.41%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, NUMIF is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ORRRY's competition here
NUMIF vs BTMDW Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, NUMIF is priced at $0.04, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, NUMIF's ROE is -4.41%, compared to BTMDW's ROE of -0.31%. Regarding short-term risk, NUMIF is more volatile compared to BTMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BTMDW's competition here
NUMIF vs EVGRF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, EVGRF has a market cap of 235.9M. Regarding current trading prices, NUMIF is priced at $0.04, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas EVGRF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to EVGRF's ROE of +0.21%. Regarding short-term risk, NUMIF is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check EVGRF's competition here
NUMIF vs MKLNF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MKLNF has a market cap of 217.6M. Regarding current trading prices, NUMIF is priced at $0.04, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, NUMIF's ROE is -4.41%, compared to MKLNF's ROE of +0.14%. Regarding short-term risk, NUMIF is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MKLNF's competition here
NUMIF vs MFCSF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MFCSF has a market cap of 198.2M. Regarding current trading prices, NUMIF is priced at $0.04, while MFCSF trades at $10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MFCSF's P/E ratio is 5.65. In terms of profitability, NUMIF's ROE is -4.41%, compared to MFCSF's ROE of +0.90%. Regarding short-term risk, NUMIF is more volatile compared to MFCSF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MFCSF's competition here
NUMIF vs CHHHF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, CHHHF has a market cap of 135M. Regarding current trading prices, NUMIF is priced at $0.04, while CHHHF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas CHHHF's P/E ratio is -107.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to CHHHF's ROE of -0.02%. Regarding short-term risk, NUMIF is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CHHHF's competition here
NUMIF vs COLRF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, NUMIF is priced at $0.04, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas COLRF's P/E ratio is -8.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to COLRF's ROE of +0.01%. Regarding short-term risk, NUMIF is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check COLRF's competition here
NUMIF vs VTIAF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, VTIAF has a market cap of 95.9M. Regarding current trading prices, NUMIF is priced at $0.04, while VTIAF trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas VTIAF's P/E ratio is -6.87. In terms of profitability, NUMIF's ROE is -4.41%, compared to VTIAF's ROE of -0.63%. Regarding short-term risk, NUMIF is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check VTIAF's competition here
NUMIF vs MCIOF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, NUMIF is priced at $0.04, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, NUMIF's ROE is -4.41%, compared to MCIOF's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCIOF's competition here
NUMIF vs ASSF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, NUMIF is priced at $0.04, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ASSF's P/E ratio is -33.33. In terms of profitability, NUMIF's ROE is -4.41%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, NUMIF is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ASSF's competition here
NUMIF vs KONEF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, KONEF has a market cap of 44.3M. Regarding current trading prices, NUMIF is priced at $0.04, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas KONEF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, NUMIF is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check KONEF's competition here
NUMIF vs USNU Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, NUMIF is priced at $0.04, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas USNU's P/E ratio is -9.41. In terms of profitability, NUMIF's ROE is -4.41%, compared to USNU's ROE of -0.55%. Regarding short-term risk, NUMIF is more volatile compared to USNU. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check USNU's competition here
NUMIF vs NVLPF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NVLPF has a market cap of 20.8M. Regarding current trading prices, NUMIF is priced at $0.04, while NVLPF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NVLPF's P/E ratio is 23.82. In terms of profitability, NUMIF's ROE is -4.41%, compared to NVLPF's ROE of +0.01%. Regarding short-term risk, NUMIF is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NVLPF's competition here
NUMIF vs HQDA Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, NUMIF is priced at $0.04, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas HQDA's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HQDA's competition here
NUMIF vs FPCG Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, NUMIF is priced at $0.04, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas FPCG's P/E ratio is 0.09. In terms of profitability, NUMIF's ROE is -4.41%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FPCG's competition here
NUMIF vs HLYK Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, HLYK has a market cap of 8.5M. Regarding current trading prices, NUMIF is priced at $0.04, while HLYK trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas HLYK's P/E ratio is -1.50. In terms of profitability, NUMIF's ROE is -4.41%, compared to HLYK's ROE of +1.42%. Regarding short-term risk, NUMIF is more volatile compared to HLYK. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HLYK's competition here
NUMIF vs GBCS Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, GBCS has a market cap of 7.7M. Regarding current trading prices, NUMIF is priced at $0.04, while GBCS trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas GBCS's P/E ratio is -2.40. In terms of profitability, NUMIF's ROE is -4.41%, compared to GBCS's ROE of +0.55%. Regarding short-term risk, NUMIF is more volatile compared to GBCS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GBCS's competition here
NUMIF vs XCRT Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, XCRT has a market cap of 7.1M. Regarding current trading prices, NUMIF is priced at $0.04, while XCRT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas XCRT's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to XCRT's ROE of +0.90%. Regarding short-term risk, NUMIF is more volatile compared to XCRT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check XCRT's competition here
NUMIF vs BICX Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BICX has a market cap of 6.8M. Regarding current trading prices, NUMIF is priced at $0.04, while BICX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BICX's P/E ratio is -1.09. In terms of profitability, NUMIF's ROE is -4.41%, compared to BICX's ROE of +0.39%. Regarding short-term risk, NUMIF is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BICX's competition here
NUMIF vs VLXC Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, VLXC has a market cap of 5.7M. Regarding current trading prices, NUMIF is priced at $0.04, while VLXC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas VLXC's P/E ratio is -8.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to VLXC's ROE of +0.58%. Regarding short-term risk, NUMIF is more volatile compared to VLXC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check VLXC's competition here
NUMIF vs RVLWF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RVLWF has a market cap of 5.3M. Regarding current trading prices, NUMIF is priced at $0.04, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, NUMIF's ROE is -4.41%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, NUMIF is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RVLWF's competition here
NUMIF vs RHEP Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, RHEP has a market cap of 3.8M. Regarding current trading prices, NUMIF is priced at $0.04, while RHEP trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas RHEP's P/E ratio is -0.74. In terms of profitability, NUMIF's ROE is -4.41%, compared to RHEP's ROE of +1.14%. Regarding short-term risk, NUMIF is more volatile compared to RHEP. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RHEP's competition here
NUMIF vs EPWCF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, NUMIF is priced at $0.04, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check EPWCF's competition here
NUMIF vs GRST Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, GRST has a market cap of 2.3M. Regarding current trading prices, NUMIF is priced at $0.04, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas GRST's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to GRST's ROE of +0.28%. Regarding short-term risk, NUMIF is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GRST's competition here
NUMIF vs TOKIF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, TOKIF has a market cap of 1.8M. Regarding current trading prices, NUMIF is priced at $0.04, while TOKIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, NUMIF is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check TOKIF's competition here
NUMIF vs SMAS Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, NUMIF is priced at $0.04, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas SMAS's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to SMAS's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check SMAS's competition here
NUMIF vs MDGP Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, NUMIF is priced at $0.04, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MDGP's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, NUMIF is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MDGP's competition here
NUMIF vs NOVC Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, NUMIF is priced at $0.04, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NOVC's P/E ratio is -0.20. In terms of profitability, NUMIF's ROE is -4.41%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, NUMIF is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NOVC's competition here
NUMIF vs PHMB Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, NUMIF is priced at $0.04, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas PHMB's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to PHMB's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check PHMB's competition here
NUMIF vs JNHMF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, JNHMF has a market cap of 870.6K. Regarding current trading prices, NUMIF is priced at $0.04, while JNHMF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas JNHMF's P/E ratio is -0.17. In terms of profitability, NUMIF's ROE is -4.41%, compared to JNHMF's ROE of +0.47%. Regarding short-term risk, NUMIF is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check JNHMF's competition here
NUMIF vs GNOW Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, NUMIF is priced at $0.04, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas GNOW's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GNOW's competition here
NUMIF vs ERUC Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ERUC has a market cap of 638.1K. Regarding current trading prices, NUMIF is priced at $0.04, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ERUC's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to ERUC's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to ERUC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ERUC's competition here
NUMIF vs JRSS Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, JRSS has a market cap of 507.6K. Regarding current trading prices, NUMIF is priced at $0.04, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas JRSS's P/E ratio is -0.06. In terms of profitability, NUMIF's ROE is -4.41%, compared to JRSS's ROE of +1.88%. Regarding short-term risk, NUMIF is more volatile compared to JRSS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JRSS's competition here
NUMIF vs DPAT Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, DPAT has a market cap of 481.6K. Regarding current trading prices, NUMIF is priced at $0.04, while DPAT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas DPAT's P/E ratio is -2.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, NUMIF is more volatile compared to DPAT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check DPAT's competition here
NUMIF vs MSITF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, NUMIF is priced at $0.04, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MSITF's P/E ratio is -0.10. In terms of profitability, NUMIF's ROE is -4.41%, compared to MSITF's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check MSITF's competition here
NUMIF vs FCHS Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, FCHS has a market cap of 392.2K. Regarding current trading prices, NUMIF is priced at $0.04, while FCHS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas FCHS's P/E ratio is -0.13. In terms of profitability, NUMIF's ROE is -4.41%, compared to FCHS's ROE of +0.08%. Regarding short-term risk, NUMIF is more volatile compared to FCHS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FCHS's competition here
NUMIF vs KJFI Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, KJFI has a market cap of 374.6K. Regarding current trading prices, NUMIF is priced at $0.04, while KJFI trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas KJFI's P/E ratio is -0.06. In terms of profitability, NUMIF's ROE is -4.41%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to KJFI. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check KJFI's competition here
NUMIF vs ARPC Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, NUMIF is priced at $0.04, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ARPC's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, NUMIF is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ARPC's competition here
NUMIF vs BNYN Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, NUMIF is priced at $0.04, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BNYN's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, NUMIF is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check BNYN's competition here
NUMIF vs NXGT Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NXGT has a market cap of 281.1K. Regarding current trading prices, NUMIF is priced at $0.04, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NXGT's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to NXGT's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to NXGT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NXGT's competition here
NUMIF vs DRWN Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, DRWN has a market cap of 239.8K. Regarding current trading prices, NUMIF is priced at $0.04, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas DRWN's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, NUMIF is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check DRWN's competition here
NUMIF vs SETO Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, SETO has a market cap of 160.9K. Regarding current trading prices, NUMIF is priced at $0.04, while SETO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas SETO's P/E ratio is -1.29. In terms of profitability, NUMIF's ROE is -4.41%, compared to SETO's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check SETO's competition here
NUMIF vs TPIA Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, NUMIF is priced at $0.04, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas TPIA's P/E ratio is -0.15. In terms of profitability, NUMIF's ROE is -4.41%, compared to TPIA's ROE of +0.55%. Regarding short-term risk, NUMIF is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check TPIA's competition here
NUMIF vs AMBD Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, NUMIF is priced at $0.04, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas AMBD's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, NUMIF is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check AMBD's competition here
NUMIF vs NMHLY Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, NUMIF is priced at $0.04, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, NUMIF's ROE is -4.41%, compared to NMHLY's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NMHLY's competition here
NUMIF vs CLRD Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, CLRD has a market cap of 40.6K. Regarding current trading prices, NUMIF is priced at $0.04, while CLRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas CLRD's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, NUMIF is more volatile compared to CLRD. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CLRD's competition here
NUMIF vs HSMD Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, HSMD has a market cap of 19.2K. Regarding current trading prices, NUMIF is priced at $0.04, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas HSMD's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, NUMIF is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HSMD's competition here
NUMIF vs SCAL Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, NUMIF is priced at $0.04, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas SCAL's P/E ratio is 0.04. In terms of profitability, NUMIF's ROE is -4.41%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check SCAL's competition here
NUMIF vs CEVE Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, CEVE has a market cap of 15.4K. Regarding current trading prices, NUMIF is priced at $0.04, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas CEVE's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, NUMIF is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CEVE's competition here
NUMIF vs GENN Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, NUMIF is priced at $0.04, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas GENN's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to GENN's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check GENN's competition here
NUMIF vs CHCR Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, NUMIF is priced at $0.04, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas CHCR's P/E ratio is -0.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to CHCR's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CHCR's competition here
NUMIF vs ACGI Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, NUMIF is priced at $0.04, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas ACGI's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, NUMIF is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ACGI's competition here
NUMIF vs NRTSF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NRTSF has a market cap of 7.8K. Regarding current trading prices, NUMIF is priced at $0.04, while NRTSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NRTSF's P/E ratio is 0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to NRTSF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check NRTSF's competition here
NUMIF vs NAFS Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NAFS has a market cap of 7K. Regarding current trading prices, NUMIF is priced at $0.04, while NAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NAFS's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, NUMIF is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NAFS's competition here
NUMIF vs PRMD Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, PRMD has a market cap of 5.6K. Regarding current trading prices, NUMIF is priced at $0.04, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas PRMD's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, NUMIF is more volatile compared to PRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check PRMD's competition here
NUMIF vs MSGP Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MSGP has a market cap of 5.2K. Regarding current trading prices, NUMIF is priced at $0.04, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MSGP's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, NUMIF is more volatile compared to MSGP. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MSGP's competition here
NUMIF vs SLHPF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, NUMIF is priced at $0.04, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas SLHPF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check SLHPF's competition here
NUMIF vs WEQL Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, WEQL has a market cap of 3.5K. Regarding current trading prices, NUMIF is priced at $0.04, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas WEQL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, NUMIF is more volatile compared to WEQL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check WEQL's competition here
NUMIF vs BBAL Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, NUMIF is priced at $0.04, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BBAL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, NUMIF is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BBAL's competition here
NUMIF vs PAOG Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, PAOG has a market cap of 2.5K. Regarding current trading prices, NUMIF is priced at $0.04, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas PAOG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to PAOG's ROE of +0.05%. Regarding short-term risk, NUMIF is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check PAOG's competition here
NUMIF vs NMMCF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, NUMIF is priced at $0.04, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, NUMIF's ROE is -4.41%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check NMMCF's competition here
NUMIF vs PPRG Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, NUMIF is priced at $0.04, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas PPRG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, NUMIF is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check PPRG's competition here
NUMIF vs OHAQ Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, NUMIF is priced at $0.04, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, NUMIF's ROE is -4.41%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check OHAQ's competition here
NUMIF vs BNKL Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, NUMIF is priced at $0.04, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas BNKL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, NUMIF is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BNKL's competition here
NUMIF vs MAHN Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, MAHN has a market cap of 1.2K. Regarding current trading prices, NUMIF is priced at $0.04, while MAHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas MAHN's P/E ratio is 0.05. In terms of profitability, NUMIF's ROE is -4.41%, compared to MAHN's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check MAHN's competition here
NUMIF vs SLHGF Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, SLHGF has a market cap of 398. Regarding current trading prices, NUMIF is priced at $0.04, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas SLHGF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to SLHGF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check SLHGF's competition here
NUMIF vs NMSCA Comparison August 2025
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 12.6M. In comparison, NMSCA has a market cap of 275. Regarding current trading prices, NUMIF is priced at $0.04, while NMSCA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -1.31, whereas NMSCA's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is -4.41%, compared to NMSCA's ROE of +0.02%. Regarding short-term risk, NUMIF is more volatile compared to NMSCA. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NMSCA's competition here